DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
144.43
+0.67 (0.47%)
At close: May 12, 2025, 4:00 PM
143.89
-0.54 (-0.37%)
After-hours: May 12, 2025, 7:59 PM EDT
DaVita Market Cap
DaVita has a market cap or net worth of $11.10 billion as of May 12, 2025. Its market cap has decreased by -4.64% in one year.
Market Cap
11.10B
Enterprise Value
22.91B
1-Year Change
-4.64%
Ranking
Category
Stock Price
$144.43
Market Cap Chart
Since December 1, 1998, DaVita's market cap has increased from $2.13B to $11.10B, an increase of 421.24%. That is a compound annual growth rate of 6.44%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 9, 2025 | 11.50B | -6.22% |
Dec 31, 2024 | 12.26B | 28.21% |
Dec 29, 2023 | 9.56B | 42.17% |
Dec 30, 2022 | 6.73B | -41.96% |
Dec 31, 2021 | 11.59B | -11.84% |
Dec 31, 2020 | 13.15B | 35.12% |
Dec 31, 2019 | 9.73B | 13.92% |
Dec 31, 2018 | 8.54B | -35.50% |
Dec 29, 2017 | 13.24B | 4.50% |
Dec 30, 2016 | 12.67B | -13.84% |
Dec 31, 2015 | 14.71B | -9.63% |
Dec 31, 2014 | 16.28B | 20.76% |
Dec 31, 2013 | 13.48B | 27.83% |
Dec 31, 2012 | 10.54B | 48.76% |
Dec 30, 2011 | 7.09B | 4.94% |
Dec 31, 2010 | 6.75B | 12.51% |
Dec 31, 2009 | 6.00B | 16.67% |
Dec 31, 2008 | 5.15B | -14.42% |
Dec 31, 2007 | 6.01B | 1.64% |
Dec 29, 2006 | 5.92B | 14.86% |
Dec 30, 2005 | 5.15B | 33.49% |
Dec 31, 2004 | 3.86B | 55.30% |
Dec 31, 2003 | 2.48B | 66.45% |
Dec 31, 2002 | 1.49B | -27.85% |
Dec 31, 2001 | 2.07B | 47.63% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 677.87B |
Johnson & Johnson | 370.90B |
UnitedHealth Group | 343.41B |
AbbVie | 335.67B |
Novo Nordisk | 292.03B |
Abbott Laboratories | 229.47B |
Novartis AG | 213.30B |
AstraZeneca | 210.42B |